Merck Drug Price Row Loss, $56M Biotech Verdict And More
By Gianna Ferrarin · August 25, 2026, 8:00 PM EDT
A D.C. federal court rejected Merck's challenge to the Medicare drug price negotiation program, finding its voluntary participation in federal drug programs precludes its constitutional takings claim....
To view the full article, register now.